Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts

The programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis plays a central role in suppression of anti-tumor immunity. Blocking the axis by targeting PD-L1 with monoclonal antibodies is an effective and already clinically approved approach to treat cancer patients. Glyco-engineering techno...

Descripción completa

Detalles Bibliográficos
Autores principales: Goletz, Christoph, Lischke, Timo, Harnack, Ulf, Schiele, Phillip, Danielczyk, Antje, Rühmann, Johanna, Goletz, Steffen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054930/
https://www.ncbi.nlm.nih.gov/pubmed/30061887
http://dx.doi.org/10.3389/fimmu.2018.01614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054930/
https://www.ncbi.nlm.nih.gov/pubmed/30061887
http://dx.doi.org/10.3389/fimmu.2018.01614

Ejemplares similares